2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Lymphoma
7
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Primary Myelofibrosis
3
Hereditary Sensory and Autonomic Neuropathies
2
Breast Neoplasms
2
Advanced Malignancies
2
Unresectable or Metastatic Solid Tumors
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Rituximab
313
Cyclophosphamide
286
fludarabine phosphate
213
fludarabine
140
ibrutinib
121
Peripheral Blood Stem Cell Transplantation
116
venetoclax
108
Mycophenolic Acid
102
obinutuzumab
88
Lenalidomide
88
Bendamustine Hydrochloride
87
Whole-Body Irradiation
85
Filgrastim
84
Tacrolimus
78
Cyclosporine
78
Busulfan
70
Melphalan
65
Radiotherapy
63
Antilymphocyte Serum
61
Alemtuzumab
58
Etoposide
56
acalabrutinib
54
Methotrexate
49
ofatumumab
46
idelalisib
38
Cytarabine
33
Chlorambucil
33
zanubrutinib
31
sargramostim
30
Specimen Handling
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
parsaclisib
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts